Cargando…
Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage
Background: Mortality of oral anticoagulation-associated ICH is around 60%, with oral anticoagulation increasing the risk of ICH seven to ten-fold compared to no anticoagulation. Current guidelines recommend DOACs (direct oral anticoagulants) as first-line therapy in the treatment of VTE (Venous Th...
Autores principales: | Troyer, Camille, Nguyen, Wesley, Xie, Annie, Wimer, Dexter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925509/ https://www.ncbi.nlm.nih.gov/pubmed/36355324 http://dx.doi.org/10.1007/s11239-022-02715-4 |
Ejemplares similares
-
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis
por: Costa, Olivia S., et al.
Publicado: (2022) -
Rapid Detection of Apixaban by a ROTEM-Based Approach and Reversibility with Andexanet Alfa or DOAC-Stop
por: Taune, Viktor, et al.
Publicado: (2022) -
Andexanet Alfa for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage: Observational Cohort Study
por: Rauch, Sebastian, et al.
Publicado: (2022) -
Andexanet Alfa Versus Prothrombin
Complex Concentrates/Blood Products
as Apixaban/Rivaroxaban Reversal Agents:
A Survey Among Pediatric Hematologists
por: Rodriguez, Vilmarie, et al.
Publicado: (2022) -
In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra
por: Brinkman, Herm Jan M., et al.
Publicado: (2022)